This HTML5 document contains 108 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00721/identifier/national-drug-code-directory/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/mesh/concept/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00721/identifier/chemspider/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00721/identifier/chebi/
n17http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00721/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n9http://www.drugs.com/mtm/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00721/identifier/pharmgkb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00721/identifier/kegg-compound/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00721/identifier/pubchem-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00721/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00721/identifier/drugbank/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00721/identifier/iuphar/
n14http://linked.opendata.cz/resource/atc/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00721/identifier/guide-to-pharmacology/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00721
rdf:type
n3:Drug
n3:description
A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). [PubChem]
n3:generalReferences
# Gentry CL, Lukas RJ: Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes. J Pharmacol Exp Ther. 2001 Dec;299(3):1038-48. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11714893
n3:group
investigational approved
n3:halfLife
7.7 minutes
n3:indication
Used as a local anesthetic primarily in oral surgery
n3:manufacturer
n10:271B4DC6-363D-11E5-9242-09173F13E4C5 n10:271B4DC4-363D-11E5-9242-09173F13E4C5 n10:271B4DC5-363D-11E5-9242-09173F13E4C5 n10:271B4DC2-363D-11E5-9242-09173F13E4C5 n10:271B4DC3-363D-11E5-9242-09173F13E4C5 n10:271B4DC0-363D-11E5-9242-09173F13E4C5 n10:271B4DC1-363D-11E5-9242-09173F13E4C5 n10:271B4DBE-363D-11E5-9242-09173F13E4C5 n10:271B4DBF-363D-11E5-9242-09173F13E4C5 n10:271B4DBC-363D-11E5-9242-09173F13E4C5 n10:271B4DBD-363D-11E5-9242-09173F13E4C5 n10:271B4DBB-363D-11E5-9242-09173F13E4C5
owl:sameAs
n16:DB00721 n17:DB00721
dcterms:title
Procaine
adms:identifier
n19:Procaine n20:46507724 n21:PA451110 n22:4914 n23:C07375 n24:61570-085-10 n25:4291 n26:4291 n27:DB00721 n28:8430 n29:4745
n3:mechanismOfAction
Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.
n3:packager
n10:271B4DB1-363D-11E5-9242-09173F13E4C5 n10:271B4DB4-363D-11E5-9242-09173F13E4C5 n10:271B4DB5-363D-11E5-9242-09173F13E4C5 n10:271B4DB2-363D-11E5-9242-09173F13E4C5 n10:271B4DB3-363D-11E5-9242-09173F13E4C5 n10:271B4DB8-363D-11E5-9242-09173F13E4C5 n10:271B4DB9-363D-11E5-9242-09173F13E4C5 n10:271B4DB6-363D-11E5-9242-09173F13E4C5 n10:271B4DB7-363D-11E5-9242-09173F13E4C5 n10:271B4DBA-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
With normal kidney function, the drug is excreted rapidly by tubular excretion.
n3:synonym
2-Diethylaminoethyl p-aminobenzoate 4-Aminobenzoic acid 2-diethylaminoethyl ester Procaine Procainum beta-(Diethylamino)ethyl 4-aminobenzoate Vitamin H3 β-(diethylamino)ethyl p-aminobenzoate β-(diethylamino)ethyl 4-aminobenzoate Procaina p-Aminobenzoic acid 2-diethylaminoethyl ester beta-(Diethylamino)ethyl P-aminobenzoate Novocaine
n11:hasAHFSCode
n12:72-00-00 n12:24-04-04-04
n3:salt
n5:hasConcept
n6:M0017615
foaf:page
n9:procaine.html
n3:IUPAC-Name
n4:271B4DD5-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4DDB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4DDA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4DD7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4DD8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4DD9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4DD3-363D-11E5-9242-09173F13E4C5 n4:271B4DEA-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4DD1-363D-11E5-9242-09173F13E4C5 n4:271B4DD4-363D-11E5-9242-09173F13E4C5 n4:271B4DEC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4DD2-363D-11E5-9242-09173F13E4C5 n4:271B4DED-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4DEE-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n14:S01HA05 n14:C05AD05 n14:N01BA02
n3:H-Bond-Acceptor-Count
n4:271B4DE1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4DE2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4DDC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4DDD-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4DDF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4DDE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4DE0-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
59-46-1
n3:category
n3:containedIn
n7:271B4DCA-363D-11E5-9242-09173F13E4C5 n7:271B4DCB-363D-11E5-9242-09173F13E4C5 n7:271B4DCE-363D-11E5-9242-09173F13E4C5 n7:271B4DCF-363D-11E5-9242-09173F13E4C5 n7:271B4DCC-363D-11E5-9242-09173F13E4C5 n7:271B4DCD-363D-11E5-9242-09173F13E4C5 n7:271B4DD0-363D-11E5-9242-09173F13E4C5 n7:271B4DC9-363D-11E5-9242-09173F13E4C5 n7:271B4DC7-363D-11E5-9242-09173F13E4C5 n7:271B4DC8-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4DE6-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4DE8-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4DE9-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4DEB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4DE5-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4DE4-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4DE7-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4DD6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4DE3-363D-11E5-9242-09173F13E4C5